241 related articles for article (PubMed ID: 29533023)
1. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses.
Bogani G; Tagliabue E; Signorelli M; Ditto A; Martinelli F; Chiappa V; Mosca L; Sabatucci I; Leone Roberti Maggiore U; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2018 May; 29(3):e40. PubMed ID: 29533023
[TBL] [Abstract][Full Text] [Related]
2. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
Janco JM; Kumar A; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Apr; 141(1):140-7. PubMed ID: 26836496
[TBL] [Abstract][Full Text] [Related]
3. A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
Cowan RA; Eriksson AGZ; Jaber SM; Zhou Q; Iasonos A; Zivanovic O; Leitao MM; Abu-Rustum NR; Chi DS; Gardner GJ
Gynecol Oncol; 2017 May; 145(2):230-235. PubMed ID: 28285846
[TBL] [Abstract][Full Text] [Related]
4. Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer.
Bogani G; Rossetti D; Ditto A; Martinelli F; Chiappa V; Mosca L; Leone Roberti Maggiore U; Ferla S; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2018 Sep; 29(5):e66. PubMed ID: 30022630
[TBL] [Abstract][Full Text] [Related]
5. The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL; Teixeira FR; Diniz TP; Faloppa CC; Mantoan H; da Costa AABA; Baiocchi G
J Gynecol Oncol; 2023 May; 34(3):e31. PubMed ID: 36731894
[TBL] [Abstract][Full Text] [Related]
6. AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer.
Muallem MZ; Gasimli K; Richter R; Almuheimid J; Nasser S; Braicu EI; Sehouli J
Anticancer Res; 2015 Jun; 35(6):3423-9. PubMed ID: 26026105
[TBL] [Abstract][Full Text] [Related]
7. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
[TBL] [Abstract][Full Text] [Related]
8. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer.
Harter P; Beutel B; Alesina PF; Lorenz D; Boergers A; Heitz F; Hils R; Kurzeder C; Traut A; du Bois A
Gynecol Oncol; 2014 Mar; 132(3):537-41. PubMed ID: 24462732
[TBL] [Abstract][Full Text] [Related]
10. [Recurrent ovarian cancer--qualification and results of surgical treatment].
Derlatkal P; Grabowska-Derlatka L; Jalinik K; Danska-Bidzińska A
Ginekol Pol; 2015 Dec; 86(12):902-6. PubMed ID: 26995939
[TBL] [Abstract][Full Text] [Related]
11. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
12. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
[TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
[TBL] [Abstract][Full Text] [Related]
14. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
15. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
16. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
17. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
18. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Harter P; Sehouli J; Reuss A; Hasenburg A; Scambia G; Cibula D; Mahner S; Vergote I; Reinthaller A; Burges A; Hanker L; Pölcher M; Kurzeder C; Canzler U; Petry KU; Obermair A; Petru E; Schmalfeldt B; Lorusso D; du Bois A
Int J Gynecol Cancer; 2011 Feb; 21(2):289-95. PubMed ID: 21270612
[TBL] [Abstract][Full Text] [Related]
19. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
[TBL] [Abstract][Full Text] [Related]
20. Secondary cytoreduction in ovarian cancer: who really benefits?
Giudice MT; D'Indinosante M; Cappuccio S; Gallotta V; Fagotti A; Scambia G; Petrillo M
Arch Gynecol Obstet; 2018 Nov; 298(5):873-879. PubMed ID: 30255344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
